Install
Endocrinology & Hormones
Thyroid, adrenal, reproductive hormones, and metabolic disorders of glands.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
- Cardiology & Metabolic Health
- Oncology & Hematology
- Neurology & Neuroscience
- Orthopedics & Sports Medicine
- Respiratory & Pulmonology
- Gastroenterology & Hepatology
- Nephrology & Urology
- Dermatology
- Rheumatology & Autoimmune
- OB‑GYN (Women’s Health)
- Pediatrics & Adolescent Health
- Geriatrics & Healthy Aging
- Ophthalmology & Vision
- ENT (Ear, Nose & Throat)
- Dentistry & Oral Health
Latest in Endocrinology & Hormones
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
1+ hour, 9+ min ago (1315+ words) Verity plans Canadian commercialization by the end of 2026 under its exclusive North American license. Lipocine (NASDAQ: LPCN) announced Health Canada approval of TLANDO capsules for testosterone replacement therapy in adult males with male hypogonadism. TLANDO has a fixed dosing regimen…...
More Life Company’s Quicksome Study Shows Rapid Sublingual Testosterone Delivery
9+ hour, 36+ min ago (169+ words) The latest announcement is out from Mountain Valley MD ( (TSE:MLCO) ). Spark’s Take on MLCO Stock According to Spark, TipRanks’ AI Analyst, MLCO is a Neutral. More about Mountain Valley MD The More Life Company Corp. is a health technology…...
Predicting Growth Response in Idiopathic Short Stature Using Advanced Mathematical Model (IMAGE)
19+ hour, 29+ min ago (77+ words) Predicting Growth Response in Idiopathic Short Stature Using Advanced Mathematical Model EurekAlert! Science News Releases New growth model captures differences in response to growth hormone therapy, integrating this predictive technology into routine pediatric practice will shift growth hormone treatment from…...
ESMO 2024: Prostate Cancer Efficacy Results from a Randomized Phase 3 Evaluation of Transdermal Estradiol Versus LHRH Agonists for Androgen Suppression in M0 Prostate Cancer
11+ hour, 30+ min ago (328+ words) ESMO 2024, Prostate Cancer, transdermal estradiol, LHRH agonists, Transdermal Estradiol Versus LHRH Agonists, Androgen Suppression in M0 Prostate Cancer, STAMPEDE trial. (UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr Ruth Langley discussing efficacy…...
The Current Landscape of Metastatic Castration-Resistant Prostate Cancer: Novel Hormonal Therapies
11+ hour, 32+ min ago (266+ words) novel hormonal therapies for mCRPC, castration resistance prostate cancer (CRPC), COU-AA-301, COU-AA-302, post-docetaxel treatment, abiraterone acetate plus prednisone in mCRPC, AFFIRM Trial, PREVAIL trial, enzalutamide in mCRPC, TRANSFORMER, combination of abiraterone and apalutamide versus abiraterone and placebo. While the emergence…...
ASCO GU 2021: Clinical Conundrums of Genomically Driven Prostate Cancer - Case Panel Discussion
11+ hour, 33+ min ago (213+ words) However, there is no data regarding chemoprevention or prophylactic therapy for germline BRCA or ATM mutational carriers. Decisions on management are best made by an interdisciplinary team of specialists, including medical genetics. The discussion then shifted to Dr. Alejandro Berlin,…...
ASCO GU 2020: Treatment Decision Making in Metastatic Prostate Cancer
11+ hour, 32+ min ago (343+ words) ASCO GU 2020 metastatic prostate cancer patient and caregiver perceptions of shared decision-making vs physician driven decision or patient driven decision, and treatment decision characteristics for men with metastatic prostate cancer. San Francisco, California (UroToday.com) Multiple treatment options exist for…...
Response to Bipolar Androgen Therapy and PD-1 Inhibition in a Patient with Metastatic Castration-Resistant Prostate Cancer and a Germline CHEK2 Mutation - Beyond the Abstract
11+ hour, 33+ min ago (437+ words) Germinline CHEK2 mutation, Bipolar Androgen Therapy (BAT), PD-1 Inhibition, Metastatic Castration-Resistant Prostate Cancer (mcrpc), androgen deprivation therapy (ADT), olaparib, docetaxel, cabazitaxel, carboplatin, palliative radiation therapy, TRANSFORMER study, COMBAT-CRPC trial, checkpoint inhibitor pneumonitis, pembrolizumab....
Loss of SNAI2 in Prostate Cancer Correlates with Clinical Response to Androgen Deprivation Therapy - Expert Commentary
11+ hour, 29+ min ago (404+ words) Loss of SNAI2 in Prostate Cancer, whole-genome sequencing, neoadjuvant treatment with LHRH agonist, AR inhibition, and AR synthesis inhibition, short-term ADT, epithelial-to-mesenchymal transition (EMT)....
The Latest Research on Biochemical Recurrence in Prostate Cancer - UroToday
11+ hour, 34+ min ago (381+ words) We investigated the real-world criteria and thresholds physicians use to classify patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence as high risk, and how these align with guidelines. Read More Biochemical recurrence (BCR) after radical prostatectomy occurs in up…...